| Value | ₹285.0 Cr |
|---|
NSE filing, NSE: SAIPARENT. Summary written from the filing by ALFA Finder's alert engine.
Sai Parenterals Ltd: key numbers
- Share price
- ₹480.70
- Market cap
- ₹2,124 Cr
- Revenue (annual)
- ₹381.0 Cr
- Net profit (annual)
- ₹14.26 Cr
- P/E (TTM)
- 85.2×Sector 45.9×
- Promoter holding
- 51.16%+0.00% QoQ
- FII holding
- 2.85%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sai Parenterals Ltd
All →Sai Parenterals Earnings Call Transcript: Key Takeaways
Sai Parenterals is transitioning from a standalone unit to a consolidated manufacturing and R&D powerhouse through strategic acquisitions. While revenue grew 9% sequentially, high depreciation from new assets is currently masking operating profitability gains.
Sai Parenterals Other Announcement
Sai Parenterals filed its quarterly shareholding pattern for the quarter ended 30 September 2026. Promoters and promoter group hold 51.16 per cent.
Sai Parenterals Investor Presentation: Key Takeaways
Q2/H1 FY27 deck (Sep 2026) gives no quarterly P&L figures. Highlights: 302 products, 599 registrations, FY26 export share 63%, Saicriti injectable and Noumed acquisitions.
Sai Parenterals Results Update
Sai Parenterals reported Q2FY27 consolidated revenue of Rs. 196 crore and PAT of Rs. 11 crore. Gross margin improved to 47.5%.
Sai Parenterals Acquisition
Sai Parenterals will acquire the remaining 25% stake in its 75% subsidiary SP Analytics for cash, making it wholly owned. Related-party approval was taken at the 1 November 2026 board meeting, with completion by 31 December 2026.
- Execution
- 31-12-2026
Sai Parenterals Q2 FY27 Results: Net Profit ₹10.5 Cr, Up 66.7% YoY
Sai Parenterals Ltd reported revenue from operations of ₹194.9 Cr (+264.3% YoY) and net profit of ₹10.5 Cr (+66.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹10.5 Cr · +66.7% YoY
Other fund raise announcements
All →Amba Auto Sales and Services Fund Raise of ₹161.6 Cr
Amba Auto board approved a preferential issue of up to 1.60 crore warrants at Rs 101 each. The issue aggregates Rs 161.60 Crore, subject to shareholder approval.
- Value
- ₹161.6 Cr
Jindal Capital Fund Raise of ₹16.22 Cr
Jindal Capital's board approved a rights issue of 1,08,12,149 shares at Rs.15 each, raising Rs.16.22 Crore. The issue ratio is 3:2, with record date 06 November 2026.
- Value
- ₹16.22 Cr
Rajkot Investment Trust Fund Raise of ₹48 Cr
Rajkot Investment Trust's board approved a Rs 48 Crore rights issue of equity shares. Pricing and record date will be set later by a committee.
- Value
- ₹48.00 Cr
U Y Fincorp Fund Raise of ₹187.2 Cr
U.Y. Fincorp's board approved preferential issues of warrants and equity shares aggregating Rs 187.17 Crore. The issue is subject to shareholder and regulatory approvals.
- Value
- ₹187.2 Cr
Rite Zone Chemcon India Fund Raise of ₹6.58 Cr
Rite Zone Chemcon India announced a preferential issue of 27,69,730 equity shares to 11 investors at Rs.24 each, raising about Rs.6.58 Crore. The approval awaits a shareholder vote on 23 November 2026.
- Value
- ₹6.58 Cr
Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr